FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386839556> ?p ?o ?g. }

• W4386839556 abstract "Abstract Background Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapies have been developed, but few of them have been directly compared. The aim of this network meta-analysis (NMA) was to compare the efficacy and safety of various intranasal agents for the treatment of acute migraine in adult patients. Methods The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to 15 August 2023. Randomized controlled trials (RCTs) using intranasal agents (no restrictions on dose, formulation, dosing regimen or timing of the first dose) to treat adult patients with acute migraine were included. The primary efficacy endpoint was pain freedom at 2 h, and the primary safety endpoint was adverse events (AEs). The analysis process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results Nineteen studies (21 RCTs, 9738 participants) were included. Compared to the placebo, 5 mg of zolmitriptan using a conventional liquid nasal spray device was the most effective for pain freedom at 2 h [odds ratio (OR): 4.67, 95% confidence interval (CI): 3.43 to 6.43] and 24 h (OR: 5.49, 95% CI: 3.58 to 8.42) among all the interventions. Butorphanol nasal spray 1 mg was the most effective (OR: 8.62, 95% CI: 1.11 to 66.92) for pain freedom at 1 h, but with low-quality evidence. DFN-02 presented the highest freedom from nausea (OR: 4.95, 95% CI: 1.29 to 19.01) and phonophobia (OR: 5.36, 95% CI: 1.67 to 17.22) at 2 h, albeit with lower odds of achieving complete pain freedom. ROX-828 showed the highest improvement in freedom from photophobia at 2 h (OR: 4.03, 95% CI: 1.66 to 9.81). Dihydroergotamine nasal spray was significantly associated with the highest risk of AEs (OR: 9.65, 95% CI: 4.39 to 21.22) and was not recommended for routine use. Zavegepant nasal spray demonstrated the lowest risk of AEs (OR: 2.04, 95% CI: 1.37 to 3.03). The results of sensitivity analyses for the primary endpoints (pain freedom at 2 h and AEs) were generally consistent with those of the base case model. Conclusions Compared with other new intranasal-specific therapies in treating migraine attacks, zolmitriptan nasal spray 5 mg was the most effective agent for pain freedom at 2 h. Zavegepant nasal spray 10 mg had the fewest adverse side effects." @default.
• W4386839556 created "2023-09-19" @default.
• W4386839556 creator A5004393572 @default.
• W4386839556 creator A5010039956 @default.
• W4386839556 creator A5012349298 @default.
• W4386839556 creator A5020147975 @default.
• W4386839556 creator A5026480264 @default.
• W4386839556 creator A5026829703 @default.
• W4386839556 creator A5067301599 @default.
• W4386839556 creator A5080041548 @default.
• W4386839556 date "2023-09-18" @default.
• W4386839556 modified "2023-09-28" @default.
• W4386839556 title "Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis" @default.
• W4386839556 cites W1489220976 @default.
• W4386839556 cites W1495967812 @default.
• W4386839556 cites W1564158486 @default.
• W4386839556 cites W1600174947 @default.
• W4386839556 cites W1610497957 @default.
• W4386839556 cites W1737745909 @default.
• W4386839556 cites W1915266560 @default.
• W4386839556 cites W1978912984 @default.
• W4386839556 cites W1980380624 @default.
• W4386839556 cites W1983027274 @default.
• W4386839556 cites W1984816331 @default.
• W4386839556 cites W1990151540 @default.
• W4386839556 cites W1992472429 @default.
• W4386839556 cites W1995350344 @default.
• W4386839556 cites W1998990511 @default.
• W4386839556 cites W2006446835 @default.
• W4386839556 cites W2010699829 @default.
• W4386839556 cites W2017344242 @default.
• W4386839556 cites W2019660771 @default.
• W4386839556 cites W2020383200 @default.
• W4386839556 cites W2022575186 @default.
• W4386839556 cites W2029036450 @default.
• W4386839556 cites W2030192874 @default.
• W4386839556 cites W2038633449 @default.
• W4386839556 cites W2039720823 @default.
• W4386839556 cites W2045511561 @default.
• W4386839556 cites W2045670750 @default.
• W4386839556 cites W2045777987 @default.
• W4386839556 cites W2048461020 @default.
• W4386839556 cites W2052258972 @default.
• W4386839556 cites W2057556593 @default.
• W4386839556 cites W2071158748 @default.
• W4386839556 cites W2071760228 @default.
• W4386839556 cites W2073110936 @default.
• W4386839556 cites W2082901679 @default.
• W4386839556 cites W2085587616 @default.
• W4386839556 cites W2085950561 @default.
• W4386839556 cites W2089733066 @default.
• W4386839556 cites W2091808438 @default.
• W4386839556 cites W2094473459 @default.
• W4386839556 cites W2123545227 @default.
• W4386839556 cites W2125435699 @default.
• W4386839556 cites W2128758183 @default.
• W4386839556 cites W2139528130 @default.
• W4386839556 cites W2140200736 @default.
• W4386839556 cites W2144625636 @default.
• W4386839556 cites W2147700937 @default.
• W4386839556 cites W2156098321 @default.
• W4386839556 cites W2156846198 @default.
• W4386839556 cites W2157754720 @default.
• W4386839556 cites W2159748960 @default.
• W4386839556 cites W2160108110 @default.
• W4386839556 cites W2267006017 @default.
• W4386839556 cites W2414032265 @default.
• W4386839556 cites W2431645748 @default.
• W4386839556 cites W246286872 @default.
• W4386839556 cites W2513426503 @default.
• W4386839556 cites W2558697804 @default.
• W4386839556 cites W2627088493 @default.
• W4386839556 cites W2759420095 @default.
• W4386839556 cites W2801085490 @default.
• W4386839556 cites W2805078797 @default.
• W4386839556 cites W2885533788 @default.
• W4386839556 cites W2918066963 @default.
• W4386839556 cites W2960467863 @default.
• W4386839556 cites W2970684805 @default.
• W4386839556 cites W2981491950 @default.
• W4386839556 cites W2990037077 @default.
• W4386839556 cites W3011452236 @default.
• W4386839556 cites W3011743134 @default.
• W4386839556 cites W3015163167 @default.
• W4386839556 cites W3095385778 @default.
• W4386839556 cites W3107747907 @default.
• W4386839556 cites W3119151025 @default.
• W4386839556 cites W3166381176 @default.
• W4386839556 cites W3198694028 @default.
• W4386839556 cites W3205515341 @default.
• W4386839556 cites W3205751058 @default.
• W4386839556 cites W4205187819 @default.
• W4386839556 cites W4211090737 @default.
• W4386839556 cites W4254908862 @default.
• W4386839556 cites W4294215472 @default.
• W4386839556 cites W4306164358 @default.
• W4386839556 cites W4320888937 @default.
• W4386839556 doi "https://doi.org/10.1186/s10194-023-01662-6" @default.
• W4386839556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37723470" @default.
• W4386839556 hasPublicationYear "2023" @default.

• next